CA-MITOQ
13.4.2022 13:07:05 CEST | Business Wire | Press release
MitoQ Ltd. , a New Zealand-based cell health company that developed a world-first sub-cellular targeted antioxidant which directly combats cell stress, today announced a complete transformation of the brand with a fresh new design, updated visual language and sustainable packaging. MitoQ is the developer of the unique, next-generation cell health molecule with the same name, that is scientifically shown to penetrate deep within the cells to reduce cell stress. By supporting the body’s primary energy source – the mitochondria -- MitoQ is able to target cell stress and improve energy, increase exercise recovery and resilience and promote healthy aging. The patented, powerful cell technology and active ingredients in MitoQ will remain the same, but the rebrand elevates the company’s purpose, its differentiated position in the wider category and role as a pioneer of cell health with a new look and feel, including new packaging, visual communications and brand messaging.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220413005266/en/
“MitoQ is more than a supplement – it is biodesigned differently to be extraordinarily effective and safe, it’s backed by decades of independent global research and supported by clinical trials and hundreds of peer reviewed scientific publications,” said Mahara Inglis, chief executive officer of MitoQ. “Rebranding is one of the steps we are taking to raise awareness of the importance of cells for overall wellbeing and draw attention to our unique technology. All the elements in our new branding and packaging are designed to reflect the unique position we hold -- not only in the health and wellness space -- but in the emerging cellular health category which we have been pioneering for decades, and also the positive impact we make on our customers’ lives. MitoQ helps all individuals – whether they are managing a health condition, juggling busy days at work or as a parent, or those just wanting to age ‘better’ by reducing cell stress. We wanted our new brand to visually depict our proprietary science and appeal to all individuals who want to improve their health, starting at the smallest level: their cells. The new branding captures the essence of MitoQ’s purpose, unique mechanism of action and the positive user experience and we’re thrilled to introduce it to the world.”
The MitoQ rebrand was undertaken to revitalize the brand position, establish a clear point of differentiation in the category and ensure all packaging was sustainable to prevent inefficiencies that may contribute to environmental harm. To help inform the strategy and execution for the rebrand, MitoQ partnered with UK-based brand transformation consultancy, Born Ugly . Through a collaborative, agile process, Born Ugly was able to support MitoQ to more effectively define the brand’s identity, vision and purpose, including business and consumer insight generation, strategic plan development, brand definition, creation and design and brand activation. At the heart of the work was the shift of the brand’s purpose from supporting consumers to ‘power through life’ to ‘empower their purpose’ through products and experiences. The approach needed to overcome cultural differences and reasons for taking MitoQ in its key markets – primarily the U.S. and China. A unifying mindset was identified that could connect the different audiences rooted in a deep human truth that when people feel their best, they can have the most positive influence on those around them.
MitoQ’s new visual articulation was rooted in the idea that small changes can have a significant and positive ripple effect on overall health, life, and the broader community. The ‘power of small’ was the idea that influenced everything within MitoQ’s new brand, including cell-inspired packaging, imagery, illustration, animation, language, and a logo that articulates a cell universe optimized at the heart by MitoQ’s small molecule. Essentially the brand proposition is that small can be big.
“Today marks a significant milestone in the history and forward growth of our company. MitoQ is not only a reputable, innovative company pioneering new technology in the emerging cellular health category, but we are a supportive and loyal community of health-minded people who are committed to making a positive impact in the world around us,” said John Marshall, chief marketing officer at MitoQ. “This project was an intense and rewarding labor of love for the entire commercial organization. We are incredibly grateful to our strategic partners, external and internal advisors, the MitoQ team and the millions of global customers who helped provide thoughtful, invaluable feedback and perspective that led to the development of this refreshed, dynamic brand. We look forward to the commercial rollout and sharing this new brand experience with our customers across multiple global regions in the coming months.”
MitoQ is a multi-patented, advanced antioxidant molecule that delivers targeted support to the cells’ mitochondria. The mitochondria provide approximately 90% of the energy the human body needs to function. As a by-product of this energy production process, the mitochondria also produce free radicals, and with age (coupled with other external and environmental stressors), the body loses its natural resistance to diffuse them. MitoQ is bio-designed to be absorbed deep inside of the cells where it can neutralize free radicals to combat cell stress, resulting in more energy, faster exercise recovery, immune support, deeper focus and overall optimized health. For more information, visit www.mitoQ.com .
MitoQ is available globally via the brand website (www.mitoQ.com ), and Amazon.com.
About MitoQ
MitoQ is a New Zealand cellular health company that invented an advanced molecule which is clinically proven to target cells for better health. Created at the University of Otago in the 1990s, MitoQ’s unique ingredient is available in a range of cellular products designed to power the health and ambitions of every body. MitoQ’s potential benefits to health have been the subject of 12 clinical trials and over 600 independent published research papers by the likes of Harvard Medical School, UCLA and the University of Cambridge, and it holds 60 patents globally. For more information about the company and its products, visit www.mitoQ.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005266/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release
Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release
NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
